In the field of viral immunology, the LCMV gp33 peptide has emerged as a foundational tool for researchers aiming to understand cellular recognition mechanisms. As someone who frequently w Sep 27, 2016—I have a question about the epitope GP33 of LCMV. In some paper, it is indicated that the wild type GP33-41 isKAVYNFATM, yet in others, Read more orks with synthetic peptides for in vitro experimental models, I have found that the precision of these sequences is vital for consistent results. Whether you are investigating the LCMV gp33–41 epitope or testing specific variants, u by Y Liu·2007·Cited by 6—Here we showed that multiple immunizations withLCMV gp33-41peptide(KAV) in Freund's adjuvant could induce KAV-specific CD8 T cells with low expression of nderstanding the biochemical properties of this 9-aa-long peptide is essential for high-quality data.
Defining the LCMV gp33–41 Epitope
The LCMV gp33–41 sequence is a lymphocytic choreomeningitis virus (LCMV) glycoprotein segment that serves as a benchmark in immunological studies. This Class I MHC restricted epitope is widely recognized for being derived from the glycoprotein (GP33 peptide) of the virus.
When ordering this reagent, you will often see it listed as a single peptide (KAVYNFATM) for stimulation of murine LCMV gp33-specific CD8+ T-cells. The standard KAVYNFATM sequence is the wild-type version, although some studies utilize the KAVYNFATC sequence, which also covers the 33-41 range and maintains high affinity for the H-2Db molecule.
Key Characteristics and Specifications
For those of us managing laboratory i Data Sheet LCMV gp33 peptide KAVYNFATM nventories, the quality of the peptide is paramount. Most reputable suppliers offer this peptide with a guarantee H2-Db | LCMV gp 33-41 | KAVYNFATC d purity of >70% or >95%.
* Sequence: KAVYNFATM (or KAVYNFATC for specific variants).
* Length: 9 amino acids.
* Restriction: H-2Db MHC Class I.
* Function: Acts as a critical component in the study of viral immunology.
In my experience, the LCMV GP33 CD8 epitope is remarkably stable when stored correctly at -20°C or -80°C in lyophilized form. It is frequently employed in assays involving GP33 peptide–treated mice or to calibrate LCMV-derived peptide responses in controlled settings.
Variations and Research Flexibility
The research community often explores modifications to the native sequence. For instance, the l- to d-amino acid substitution in the immunodominant LCMV-derived epitope gp33 has provided deep insights into how T-cell receptors (TCR) distinguish between subtle chemical changes.
Furthermore, when discussing GP(33-41), a 9-aa-long peptide, it is important to note its role in upregulating H-2Db molecules. Whether you are looking for a GP33 tetramer or a basic KAVYNFATC preparation, ensure that the source pro Lymphocytic Choriomeningitis Virus (LCMV) Disease Fact Sheet vides a clear certificate of analysis. I have found that even minor variations, such as those involving 43 residues or carboxyl-extended versions, can significantly alter binding kinetics.
Practical Considerations for Laboratory Use
When working with LCMV, specifically the gp 33 protein, consistency is your best asset. The LCMV gp33–41 H-2Db complex is the gold standard for studying T-cell activation. If you are performing stimulation assays, ensure your LCMV gp33-41 is reconstituted according to the manufacturer's buffer recommendations to avoi Prenatal Diagnosis of Congenital Lymphocytic Choriomeningitis Virus d aggregation.
The LCMV gp33 remains one of the most reliable antigens for those studying immune responses in a laboratory environment. By focusing on high-purity peptides and strictly following established protocols for GP33, researchers can continue to push the boundaries of our understanding of viral recognition without the need for complex, in-human variables. Always verify your sequence—whether KAVYNFATM or the C-peptide variant—to ensure it aligns with the specific parameters of your experimental design.